Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment - Hampel, H; Teipel, S J; Fuchsberger, T; Andreasen, N; Wiltfang, J; Otto, M; Shen, Y; Dodel, R; Du, Y; Farlow, M; Möller, H-J; Blennow, K; et al. (Molecular psychiatry, 2004)
Keywords: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Apolipoprotein E; Apolipoprotein E4; Apolipoproteins E - genetics; Behavioral Sciences; Biological and medical sciences; Biological Psychology; Biomarkers; Cerebrospinal fluid; Cognition Disorders - cerebrospinal fluid; Cognition Disorders - diagnosis; Cognition Disorders - genetics; Cognitive ability; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Female; Humans; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Neurodegenerative diseases; Neurology; Neurosciences; original-research-article; Patients; Peptide Fragments - cerebrospinal fluid; Pharmacotherapy; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proteins; Psychiatry; Sensitivity and Specificity; Severity of Illness Index; Tau protein; tau Proteins - cerebrospinal fluid; beta-amyloid; early diagnosis; mild cognitive impairment (MCI); prediction; Alzheimer's disease (AD); tau; cerebro-spinal fluid (CSF); biomarker; prognosis; conversion; Human; Nervous system diseases; Tau protein; Alzheimer disease; β Amyloid protein; Predictor; Central nervous system disease; Degenerative disease; mild cognitive impairment; Cerebrospinal fluid; Cerebral disorder